Integrated European omics research project for diagnosis and therapy in rare ne...
Integrated European omics research project for diagnosis and therapy in rare neuromuscular and neurodegenerative diseases
Neurodegenerative (ND) and neuromuscular (NM) disease is one of the most frequent classes of rare diseases, affecting life and mobility of 500,000 patients in Europe and millions of their caregivers, family members and employers....
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
PTQ-14-07332
Diseño y aplicación de técnicas de secuenciación masiva para...
53K€
Cerrado
BIO-NMD
Identifying and validating pre clinical biomarkers for diagn...
8M€
Cerrado
INC-FPGS-2010-0788
Alta eficiencia en la búsqueda de nuevos biomarcadores epige...
39K€
Cerrado
PTQ-13-06020
Desarrollo de plataformas diagnósticas basadas en secuenciac...
65K€
Cerrado
PTQ-10-03460
Implementación de tecnologías de secuenciación masiva y apli...
21K€
Cerrado
PROSEQO
PROtein SEQuencing using Optical single molecule real time d...
3M€
Cerrado
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Neurodegenerative (ND) and neuromuscular (NM) disease is one of the most frequent classes of rare diseases, affecting life and mobility of 500,000 patients in Europe and millions of their caregivers, family members and employers. This NEUROMICS project brings together the leading research groups in Europe, five highly innovative SMEs and relevant oversea experts using the most sophisticated Omics technologies to revolutionize diagnostics and to develop pathomechanism-based treatment for ten major ND and NM diseases. Specifically we aim to:
(i) use next generation WES to increase the number of known gene loci for the most heterogeneous disease groups from about 50% to 80%,
(ii) increase patient cohorts by large scale genotyping by enriched gene variant panels and NGS of so far unclassified patients and subsequent phenotyping,
(iii) develop biomarkers for clinical application with a strong emphasis on presymptomatic utility and cohort stratification,
(iv) combine -omics approaches to better understand pathophysiology and identify therapeutic targets,
(v) identify disease modifiers in disease subgroups cohorts with extreme age of onset
(vi) develop targeted therapies (to groups or personalized) using antisense oligos and histone deacetylase inhibitors, translating the consortiums expertise in clinical development from ongoing trials toward other disease groups, notably the PolyQ diseases and other NMD.
To warrant that advances affect a large fraction of patients we limited the selection to a number of major categories, some of which are in a promising stage of etiological and therapeutic research while some others are in great need of further classification. The efforts will be connected through a NEUROMICS platform for impact, communication and innovation that will provide tools and procedures for ensuring trial-readiness, WP performance, sustainability, interaction with the chosen Support IRDiRC and RD-Connect project and involvement of stakeholders in the NDD/NMD field.